Abstract 162P
Background
It was unclear whether neutrophil/lymphocyte ratio (NLR) in gastric cancer patients are related to anastomotic leakage (AL). We aimed to evaluate the monitoring value of NLR for AL after radical gastrectomy for gastric cancer.
Methods
Two thousand eight hundred and fifty-five patients receiving radical total gastrectomy with Roux-en-Y esophagojejunal anastomosis for gastric cancer were included, and the cumulative sum (CUSUM) curve was used to dynamically monitor NLR changes.
Results
The incidence of AL was 2.6% (75/2855). The median diagnosis time for AL was 7 (2-17) days, and the median healing time was 19 (5-98) days. According to the CUSUM exceeded the limit value (3σ: 3 standard deviations) or not, the patients were divided into ≥3σ group and <3σ group. The 5 dead patients were in the ≥3σ group, and the median healing time of the other patients was 32 (7-98) days, which was longer than that of patients in the <3σ group [11 (5-28) days, p<0.001]. And 43.5% of patients in the ≥3σ group had severe complications (Clavien-Dindo grade ≥3), which were higher than those in the <3σ group (17.2%, p=0.019). Baseline NLR <2.5, AL occurred <7 days, and CUSUM change ≥3σ were independent risk factors affecting delayed healing (>19 days) or death. The area under curve (AUC) of receiver operating characteristic (ROC) of the scoring system was 0.913. The healing rate of patients in low, medium and high-risk group ≤19 days was 95.7%, 47.4% and 6.1%, respectively.
Conclusions
NLR can dynamically monitor the healing process of AL. The scoring system constructed based on NLR can effectively identify high-risk populations with delayed AL healing or death, providing an objective basis to develop a reasonable treatment plan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
372P - Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study
Presenter: Ross A. Soo
Session: e-Poster Display Session
373P - Chromatin accessibility reveals potential prognostic value of the peak set associated with smoking history in patients with lung adenocarcinoma
Presenter: Jianlian Deng
Session: e-Poster Display Session
384P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: e-Poster Display Session
385P - Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
Presenter: Fabrice Barlesi
Session: e-Poster Display Session
386P - A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: LI Zhou
Session: e-Poster Display Session
387P - Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
Presenter: Tomonori Hirashima
Session: e-Poster Display Session
388P - Biosimilar TAB008 compared with bevacizumab in advanced non-squamous, non-small cell, EGFR wildtype lung cancer patients
Presenter: Zhen Zhou
Session: e-Poster Display Session
389P - Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
Presenter: Yi-Long Wu
Session: e-Poster Display Session
391P - Economic impact of next-generation sequencing (NGS) versus single-gene testing modalities to detect genomic alterations (GAs) in metastatic non-small cell lung cancer (mNSCLC) in Asia
Presenter: Herbert Loong
Session: e-Poster Display Session
392P - Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-positive non-small cell lung cancer patients with brain metastases in China
Presenter: Zhixin Qiu
Session: e-Poster Display Session